No Detail Found!

RESPONSE TO IMMUNOSUPPRESSIVE THERAPY IN PATIENTS OF ACQUIRED APLASTIC ANAEMIA: A SINGLE CENTER EXPERIENCE FROM A DEVELOPING COUNTRY

Author(s)
Maryam Khan Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Raheel Iftikhar Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Qamar un-Nisa Chaudhry Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Syed Kamran Mehmood Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Tehniat Faraz Dow University of Health Sciences,Karachi ,Pakistan
Tariq Ghafoor Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Nighat Shahbaz Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Mehreen Ali Khan Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Ghassan Umair Shamshad Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Tariq Azam Khattak Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Abstract
Background: Aplastic Anaemia (AA) is characterized by pancytopenia and hypocellular marrow. Immunosuppressive therapy (IST) SHOWS impressive haematological response; however, risk of relapse and clonal evolution persists. The objective of the study is to assess response to IST in patients with aplastic anaemia. Methods: A retrospective single centre study at AFBMTC / NIBMT for patients of acquired AA was conducted from January 2005 to December 2019.Inclusion criteria included diagnosed cases of acquired AA receiving IST for at least 12 weeks and age >2 years. IST included cyclosporine (CsA) alone, CsA + androgens, CsA + rabbit anti thymocyte globulin (rATG), CsA + horse anti thymocyte globulin (hATG). Primary outcome measure was response to IST; secondary outcome measure was overall survival (OS). Results: A total of 513 patients received IST. Median age was 23 years (range 2-97 years). In study cohort, 155 (30.2%) patients responded to the IST, 63 (12.3%) achieved complete response (CR) while 92 (17.9%) achieved partial response (PR). The ORR of CsA in NSAA, SAA and VSAA was 52.6%, 28.10% and 10% respectively; whereas ORR of CsA + rATG in NSAA, SAA and VSAA was 50%, 35.1% and 22.5% respectively. OS was 38% at a median follow up of 36 months. There was a significant difference in the survival distributions of different treatment modalities (p=0.016). Median survival time 60 months (CsA), 9 months (CsA+ androgens) and 39 months (CsA+ rATG/hATG.) Conclusion: In resource constrained settings, single agent CsA remains a reasonable alternative with modest activity and acceptable side effect profile.
Publication Details
Page(s) 969-973
Published Journal: Journal of Ayub Medical College, Volume: 34, Issue: 4, Year: 2022

Request the full text from PASTIC

Keywords
Cyclosporine, Aplastic anaemia, Immunosuppressive therapy
0

Citations

0

Downloads

66

Views